A Multicenter, Open-Label, Single Arm, Long Term Extension Study of WA 19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Roche
- 01 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 11 May 2015 Planned End Date changed from 1 Apr 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
- 11 May 2015 Planned primary completion date changed from 1 Apr 2015 to 1 May 2015 as reported by ClinicalTrials.gov.